Clinical Trial Update: Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of Forodesine (BCX-1777) for patients with refractory cutaneous T-cell lymphoma (stages IIA, IIB, III, IVA, or IVB) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Forodesine (forodesine)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Lymphoma | Phase 1 | Status: COMPLETED